Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

Cancer letters - 28 Dec 2010

Jin Linhua, Tabe Yoko, Kojima Kensuke, Zhou Yixin, Pittaluga Stefania, Konopleva Marina, Miida Takashi, Raffeld Mark

Abstract excerpt

This study demonstrated a pronounced synergistic growth-inhibitory effect of an MDM2 inhibitor Nutlin-3 and a proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) cells regardless of TP53 mutant status and innate bortezomib sensitivity. In the mutant TP53 MCL cells which are intrinsically resistant to bortezomib, the combination of Nutlin-3/bortezomib synergistically induced cytotoxicity through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to bcl-2 Homologous Antagonist-Killer Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Boronic Acids

Share to Bortezomib

Share to Caspase 9

Share to Lymphoma, Mantle-Cell

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Pyrazines

Source

Identifiers

PMID: 20850924
DOI: 10.1016/j.canlet.2010.08.015

Genes

MDM2
BAX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.PMID 20850924Read ↗

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.Semantic proximity Read ↗

Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomibSemantic proximity Read ↗

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.Semantic proximity Read ↗

Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cellsSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.Semantic proximity Read ↗

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic ResponsesSemantic proximity Read ↗

Altered Apoptosis Pathways in Mantle Cell LymphomaSemantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.Semantic proximity Read ↗

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read ↗

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.